A detailed history of Rhumbline Advisers transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 37,054 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,054
Previous 36,328 2.0%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
N/A
726 Added 2.0%
37,054 $0
Q4 2023

Feb 08, 2024

SELL
N/A
-27 Reduced 0.07%
36,328 $0
Q3 2023

Nov 09, 2023

BUY
N/A
1,924 Added 5.59%
36,355 $0
Q2 2023

Aug 08, 2023

BUY
N/A
34,431 New
34,431 $0
Q2 2022

Aug 11, 2022

SELL
$2.9 - $4.44 $69,817 - $106,893
-24,075 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$3.51 - $6.74 $9,943 - $19,094
2,833 Added 13.34%
24,075 $85,000
Q4 2021

Feb 10, 2022

BUY
$6.03 - $11.67 $7,410 - $14,342
1,229 Added 6.14%
21,242 $141,000
Q3 2021

Nov 12, 2021

BUY
$9.98 - $35.22 $33,263 - $117,388
3,333 Added 19.98%
20,013 $200,000
Q2 2021

Aug 05, 2021

BUY
$24.71 - $44.28 $86,262 - $154,581
3,491 Added 26.47%
16,680 $515,000
Q1 2021

May 06, 2021

BUY
$37.62 - $60.41 $496,170 - $796,747
13,189 New
13,189 $575,000

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.